In vitro biotransformation of the new antipsychotic agent, RWJ-46344 in rat hepatic S9 fraction: API-MS/MS/MS identification of metabolites
The in vitro biotransformation of the antipsychotic agent, RWJ-46344 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-46344 (∼37% of the sample) plus 12 metabolites were profiled, quantified, and tentatively identified on the basi...
Saved in:
Published in | Journal of pharmaceutical and biomedical analysis Vol. 24; no. 2; pp. 307 - 316 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier B.V
15.12.2000
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The in vitro biotransformation of the antipsychotic agent, RWJ-46344 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-46344 (∼37% of the sample) plus 12 metabolites were profiled, quantified, and tentatively identified on the basis of API (ionspray)-MS/MS/MS data. The proposed metabolic pathways for RWJ-46344 are proposed, and the six metabolic pathways are 1,
O-dealkylation; 2, piperidinyl oxidation; 3,
N-debenzylation; 4, phenyl hydroxylation; 5, dehydration; and 6, reduction. Pathways 1 to 3 formed
O-desisopropyl RWJ-46344 (M3,∼13% of the sample) and its hydroxy-metabolite (M5,∼8%), hydroxy-piperidinyl RWJ-46344 (M1,∼5%) and a phenylpiperidinyl metabolite (M8,∼24%) as major and moderate metabolites. Eight minor metabolites (each <2%) were formed via a combination of six steps. RWJ-46344 is metabolized substantially by this rat hepatic system. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/S0731-7085(00)00421-0 |